Research programme: cancer therapeutics - Ohara Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Ohara Pharmaceuticals

Alternative Names: OP-10 series; OP-12; OP-20 series; OP-21

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Ohara Pharmaceutical
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides
  • Mechanism of Action DNA methylation inhibitors; Methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Myelodysplastic syndromes

Most Recent Events

  • 10 Jan 2017 Preclinical trials in Myelodysplastic syndromes in Japan before January 2017 (Ohara Pharamceutical pipeline, January 2017)
  • 15 Nov 2016 Preclinical trials in Colorectal cancer in Japan (unspecified route)
  • 15 Nov 2016 Preclinical data for OP 12 and OP 21 was released by OHARA Pharmaceutical
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top